Iran (Islamic Republic of)
Tuberculosis profile
Population  2012 76 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (0.7–4.7) 2.9 (0.92–6.1)
Mortality (HIV+TB only) 0.083 (0.062–0.11) 0.11 (0.08–0.14)
Prevalence  (includes HIV+TB) 25 (10–47) 33 (13–61)
Incidence  (includes HIV+TB) 16 (11–21) 21 (15–28)
Incidence (HIV+TB only) 0.29 (0.21–0.39) 0.38 (0.28–0.51)
Case detection, all forms (%) 70 (52–97)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 5 409 (51) Relapse 337 (43)
Smear-negative 1 713 (16) Treatment after failure 159 (20)
Smear-unknown / not done 478 (4) Treatment after default 39 (5)
Extrapulmonary 3 105 (29) Other 243 (31)
Other 0 (0)      
Total new 10 705   Total retreatment 778  
           
Other (history unknown) 0        
Total new and relapse 11 042   Total cases notified 11 483  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.1 1.0 0.8
Age < 15 59 164 178
Laboratories 2012
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 3.6
Drug susceptibility testing (per 5 million population) 0.5
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 85   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 83  
Retreatment 72  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 574 (14)
HIV-positive TB patients 283 (18)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 77 (27)
HIV-positive TB patients on antiretroviral therapy (ART) 117 (41)
HIV-positive people screened for TB 7 095  
HIV-positive people provided with IPT 155  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 5 (3.4–7) 48 (35–62)
MDR-TB cases among notified pulmonary
TB cases
380 (260–530) 380 (270–480)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 411 (7%) 207 (27%) 630
Laboratory-confirmed MDR-TB cases 13 35 50
Patients started on MDR-TB treatment     62
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data